HEALTH● LOWAug 12 · Aug 12, 2026, 11:37 PM
Allogene outlines plan for ~100 ALPHA3 sites by year end as FDA grants RMAT and Fast Track for cema-cel
Seeking Alpha Tech
Allogene has outlined a plan to establish approximately 100 ALPHA3 sites by the end of the year, following the FDA's granting of Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track status for cema-cel. These FDA designations suggest potential for accelerated development of the therapy.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH30m agoEbola: FG orders strict screening at Nigeria’s entry pointsPremium TimesHEALTH1h agoNew Florida counties report dengue cases as statewide total passes 400The HillHEALTH1h agoI have a disease that people are too ashamed to talk aboutBBC AfriqueHEALTH1h agoShare Your Experiences With Medicaid Claims for RepaymentNYT US